Alphamab Oncology — Board/Management Information 2020

Dec 23, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [172 x 40] intentionally omitted <==

ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the announcement (the “ Announcement ”) of Alphamab Oncology (the “ Company ”) dated December 7, 2020 in relation to, among others, change of joint company secretary of the Company. Capitalized terms used herein, unless otherwise defined, shall have the same meanings as those defined in the Announcement.

Pursuant to Rules 3.28 and 8.17 of the Listing Rules, the Company must appoint a company secretary who, by virtue of his/her academic or professional qualifications or relevant experience, is, in the opinion of the Stock Exchange, capable of discharging the functions of company secretary.

As stated in the Announcement, Ms. WANG Jin’nan (王晉南) (“ Ms. Wang ”) currently does not possess the relevant qualification as required under the Rules 3.28 and 8.17 of the Listing Rules. See the Announcement for details of Ms. Wang’s qualifications and experience. The Company has made an application to the Stock Exchange for a waiver (the “ Waiver ”) from the strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules.

The Board announces that the Stock Exchange has granted the Waiver, which is valid for a period of three years from the date of Ms. Wang’s appointment as a joint company secretary (the “ Waiver Period ”), on the following conditions:

• (i) Ms. Wang will be assisted by Ms. Chan Lok Yee (“ Ms. Chan ”), the current joint company secretary of the Company, who possesses all the requisite qualifications required by the Listing Rules during the Waiver Period;

• (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and

• (iii) the Company will disclose the details of the waiver, including reasons, details and conditions for the Waiver and the qualification and experience of both Ms. Wang and Ms. Chan, by way of an announcement.

1

Ms. Chan is currently a manager of Corporate Services of Vistra Corporate Services (HK) Limited. She has over seven years of experience in providing a full range of company secretarial and compliance services and is currently serving a portfolio of clients including public listed companies and private companies. Ms. Chan has been an associate member of The Hong Kong Institute of Chartered Secretaries and an associate member of The Institute of Chartered Secretaries and Administrators in United Kingdom since 2015.

The Wavier applies to Ms. Wang’s appointment only. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

With the Waiver granted, the Board is pleased to announce that Ms. Wang has been appointed as a Joint Company Secretary with effect from December 7, 2020.

By Order of the Board Alphamab Oncology Dr. XU Ting Chairman and Executive Director

Hong Kong, December 23, 2020

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.

2